เอกสารอ้างอิง
1. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines 2020; 8: 391. doi:10.3390/vaccines8030391.
2. Centers for disease control and prevention. Human Papillomavirus (HPV) Vaccination. 2020. Available at:
https://www.cdc.gov/vaccines/vpd/hpv/public/index.html#:~:text=Three%20HPV%20vaccines%E2%80%949%2Dvalent,that%20cause%20most%20HPV%20cancers.
Accessed on December, 15, 2020.
3. Latsuzbaia A, Arbyn M, Tapp J, et al. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg. Cancer Epidemiol. 2019; 63:101-593.
doi: 10.1016/j.canep.2019.101593.
4. Bergman H, Buckley B, Villanueva G, et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019;(11): CD013479.
doi:10.1002/14651858.CD013479.
5. Garland SM, Pitisuttithum P, Ngan H, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries. J Infect Dis. 2018;218(1):95-108. doi: 10.1093/infdis/jiy133.
6. Centers for disease control and prevention. HPV vaccine recommendations. Available at:
https://www.cdc.gov/vaccines/vpd/hpv/hcp/recommendations.html.
Accessed on December, 15, 2020.
7. World health organization. Guidelines for the prevention and control of cervical cancer. WHO. Available at:
http://www.who.int/reproductivehealth/topics/cancers/hpv-vaccination/en/.
Accessed on December, 15, 2020.
8. Huh W, Joura E, Giuliano A, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomized, double-blind trial. Lancet. 2017;390(10108):2143-2159.
doi: 10.1016/S0140-6736(17)31821-4.